Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate

Journal of the American Academy of Dermatology

Volumn 73, Issue 3, 2015, Pages 395-399

  Levy, Lauren L ^a   Urban, Jennifer ^a   King, Brett A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atopic dermatitis; Janus kinase inhibitor; tofacitinib

Indexed keywords

LIPID; PREDNISONE; TOFACITINIB; JANUS KINASE; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIVER FUNCTION; MALE; MIDDLE AGED; PRIORITY JOURNAL; RECALCITRANT ATOPIC DERMATITIS; SIDE EFFECT; TREATMENT RESPONSE; YOUNG ADULT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; DERMATITIS, ATOPIC; DOSE RESPONSE; DRUG ADMINISTRATION; EPIDEMIOLOGY; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASES; MALE; MIDDLE AGED; PIPERIDINES; PYRIMIDINES; PYRROLES; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939467958     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.06.045     Document Type: Article

References (24)

1. M.I. Asher, S. Montefort, B. Bjorksten, and et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys Lancet 368 9537 2006 733 743
2. J. Schmitt, A. Bauer, and M. Meurer Atopic eczema in adulthood Hautarzt 59 10 2008 841 850 quiz 851
3. A.S. Paller, R.O. McAlister, J.J. Doyle, and A. Jackson Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment Clin Pediatr (Phila) 41 5 2002 323 332
4. C.S. Koblenzer, and P.J. Koblenzer Chronic intractable atopic eczema: its occurrence as a physical sign of impaired parent-child relationships and psychologic developmental arrest: improvement through parent insight and education Arch Dermatol 124 11 1988 1673 1677
5. S.P. Kini, L.K. DeLong, E. Veledar, A.M. McKenzie-Brown, M. Schaufele, and S.C. Chen The impact of pruritus on quality of life: the skin equivalent of pain Arch Dermatol 147 10 2011 1153 1156
6. L.F. Eichenfield, W.L. Tom, T.G. Berger, and et al. Guidelines of care for the management of atopic dermatitis: section 2; management and treatment of atopic dermatitis with topical therapies J Am Acad Dermatol 71 1 2014 116 132
7. R. Sidbury, D.M. Davis, D.E. Cohen, and et al. Guidelines of care for the management of atopic dermatitis: section 3; management and treatment with phototherapy and systemic agents J Am Acad Dermatol 71 2 2014 327 349
8. Garritsen FM, Roekevisch E, van der Schaft J, Deinum J, Spuls PI, de Bruin-Weller MS. Ten years' experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centers. J Eur Acad Dermatol Venereol. doi:10.111/jdv.13064. Published online March 9, 2015.
9. S.F. Thomsen, T. Karlsmark, K.K. Clemmensen, and et al. Outcome of treatment with azathioprine in severe atopic dermatitis: a 5-year retrospective study of adult outpatients Br J Dermatol 172 4 2015 1122 1124
10. M.E. Schram, E. Roekevisch, M.M. Leeflang, J.D. Bos, J. Schmitt, and P.I. Spuls A randomized trial of methotrexate versus azathioprine for severe atopic eczema J Allergy Clin Immunol 128 2 2011 353 359
11. L.A. Beck, D. Thaci, J.D. Hamilton, and et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis N Engl J Med 371 2 2014 130 139
12. L. Bao, H. Zhang, and L.S. Chan The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis JAKSTAT 2 3 2013 e24137
13. B.G. Craiglow, and B.A. King Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis J Invest Dermatol 134 12 2014 2988 2990
14. G.C. Mohan, and J.I. Silverberg Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis JAMA Dermatol 151 2015 522 528
15. ClinicalTrials.gov. A phase 2a, multi-site, randomized, double-blind, vehicle-controlled, parallel-group study of the pilot efficacy, safety, tolerability, and pharmacokinetics of 2% tofacitinib ointment in subjects with mild to moderate atopic dermatitis. Available at https://clinicaltrials.gov/ct2/show/NCT02001181. Accessed March 20, 2015.
16. J. Schmitt, S. Langan, S. Deckert, and et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation J Allergy Clin Immunol 132 6 2013 1337 1347
17. J.J. O'Shea, S.M. Holland, and L.M. Staudt JAKs and STATs in immunity, immunodeficiency, and cancer N Engl J Med 368 2 2013 161 170
18. S. Goenka, and M.H. Kaplan Transcriptional regulation by STAT6 Immunol Res 50 1 2011 87 96
19. S. Sehra, H.A. Bruns, A.N. Ahyi, and et al. IL-4 is a critical determinant in the generation of allergic inflammation initiated by a constitutively active Stat6 J Immunol 180 5 2008 3551 3559
20. K. Ochiai, E. Tanabe, C. Ishihara, and et al. Role of JAK2 signal transductional pathway in activation and survival of human peripheral eosinophils by interferon-gamma (IFN-gamma) Clin Exp Immunol 118 3 1999 340 343
21. Y. Fujii, and T. Sengoku Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis Pharmacology 91 3-4 2013 207 213
22. J. Wollenhaupt, J. Silverfield, E.B. Lee, and et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studies J Rheumatol 41 5 2014 837 852
23. R. Fleischmann, M. Cutolo, M.C. Genovese, and et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis Rheum 64 3 2012 617 629
24. R. Fleischmann, J. Kremer, J. Cush, and et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis N Engl J Med 367 6 2012 495 507